Publikationsdatenbank

Live attenuated virus vaccine protects against SARS-CoV-2 variants of concern B.1.1.7 (Alpha) and B.1.351 (Beta) (2021)

Art

Zeitschriftenartikel / wissenschaftlicher Beitrag

Autoren

Trimpert, Jakob (WE 5)

Adler, Julia M. (WE 5)

Eschke, Kathrin (WE 5)

Abdelgawad, Azza (WE 5)

Firsching, Theresa C. (WE 12)

Ebert, Nadine

Thao, Tran Thi Nhu

Gruber, Achim D. (WE 12)

Thiel, Volker

Osterrieder, Nikolaus (WE 5)

Kunec, Dusan (WE 5)

Quelle

Science advances

Bandzählung: 7

Heftzählung: 49

Seiten: Artikel eabk0172

ISSN: 2375-2548

Sprache

Englisch

Verweise

URL (Volltext): https://www.science.org/doi/10.1126/sciadv.abk0172

DOI: 10.1126/sciadv.abk0172

Pubmed: 34851677

Kontakt

Institut für Virologie

Robert-von-Ostertag-Str. 7-13
14163 Berlin
+49 30 838 51833
virologie@vetmed.fu-berlin.de

Abstract / Zusammenfassung

Vaccines are instrumental and indispensable in the fight against the COVID-19 pandemic. Several recent SARS-CoV-2 variants are more transmissible and evade infection- or vaccine-induced protection. We constructed live attenuated vaccine candidates by large-scale recoding of the SARS-CoV-2 genome and showed that the lead candidate, designated sCPD9, protects Syrian hamsters from a challenge with ancestral virus. Here, we assessed immunogenicity and protective efficacy of sCPD9 in the Roborovski dwarf hamster, a nontransgenic rodent species that is highly susceptible to SARS-CoV-2 and severe COVID-19–like disease. We show that a single intranasal vaccination with sCPD9 elicited strong cross-neutralizing antibody responses against four current SARS-CoV-2 variants of concern, B.1.1.7 (Alpha), B.1.351 (Beta), B.1.1.28.1 (Gamma), and B.1.617.2 (Delta). The sCPD9 vaccine offered complete protection from COVID-19–like disease caused by the ancestral SARS-CoV-2 variant B.1 and the two variants of concern B.1.1.7 and B.1.351.